Swissdamed Goes Mandatory July 2026: Complete Guide to Swiss Medical Device Registration and UDI Compliance

Swissdamed Becomes Mandatory on July 1, 2026

On July 1, 2026, Switzerland's medical device regulatory landscape undergoes a structural change. The swissdamed database, developed by Swissmedic as Switzerland's counterpart to the EU's EUDAMED system, moves from voluntary to mandatory use. From that date forward, all medical devices, in vitro diagnostics (IVDs), and procedure packs placed on the Swiss market must be registered in swissdamed before they can be legally distributed.

For foreign manufacturers, this means engaging a Swiss Authorized Representative (CH REP), registering as an economic operator, and uploading device data with UDI identifiers to the Product Module. The requirements parallel EUDAMED closely but operate as an entirely separate system with its own deadlines, data fields, and compliance consequences.

This guide provides a complete walkthrough of swissdamed registration requirements, the July 2026 deadline, the grace period, immediate registration triggers, and practical steps manufacturers must take now.

Background: Why Switzerland Needs Its Own Database

Switzerland is not an EU member state. When the Mutual Recognition Agreement (MRA) between Switzerland and the EU for medical devices lapsed in 2021, Swissmedic could no longer rely on EU conformity assessment infrastructure. Switzerland adopted the Medical Device Ordinance (MedDO) and the In Vitro Diagnostic Ordinance (IvDO), which mirror EU MDR and IVDR requirements but apply them independently.

The practical consequence: Switzerland needed its own device registration database, just as every EU member state needs EUDAMED. Swissmedic developed swissdamed to serve this function, providing centralized device registration, UDI management, and post-market surveillance tracking for the Swiss market.

The system aligns with EUDAMED standards, meaning manufacturers familiar with EUDAMED data structures will find swissdamed's requirements familiar but not identical. Key differences include separate actor registration, a Swiss-specific CH REP framework, and a different timeline.

What Is swissdamed and What Modules Does It Include

Swissdamed is structured around several functional modules:

1. Actor Module: Registration of economic operators (manufacturers, CH REPs, importers, system/procedure pack producers) with a Swiss-specific identification number
2. UDI Devices Module (Product Module): Registration of medical devices and IVDs with UDI data, similar to EUDAMED's UDI/Device module
3. Certificates Module: Links device registrations to conformity assessment certificates
4. Market Surveillance Module: For competent authority oversight and vigilance data

The UDI Devices Module became available for voluntary submissions in August 2025. Swissmedic activated machine-to-machine (M2M) registration functionality by the end of March 2026, allowing batch data uploads through API integration. Mandatory use begins July 1, 2026.

The July 1, 2026 Deadline: What Changes

Mandatory Registration for New Devices

From July 1, 2026, any medical device, IVD, procedure pack, or MD-DEVIT product (devitalized human tissue products under Art. 2a para. 2 Therapeutic Products Act) first placed on the Swiss market must be registered in swissdamed's Product Module before distribution. "Placed on the market" means the first making available of the device in Switzerland, regardless of whether it is imported, manufactured domestically, or transferred from another market.

Grace Period for Devices Already on the Market

Devices already on the Swiss market before July 1, 2026, have a transition period until December 31, 2026. During this window, they may continue to be sold without swissdamed registration, but must be registered before the transition period expires.

The Critical Exception: Immediate Registration Trigger

There is one important exception to the grace period. If a post-market surveillance event occurs on or after July 1, 2026, involving a device that has not yet been registered in swissdamed, registration becomes immediately mandatory. This applies to:

• Incidents reportable under MedDO/ IvDO vigilance requirements
• Field Safety Corrective Actions (FSCAs)
• Trend reporting events

In practice, this means manufacturers cannot assume they have until December 31, 2026, for their entire portfolio. Any vigilance event on an unregistered device creates an immediate compliance obligation.

Who Must Register in swissdamed

Manufacturers

All manufacturers placing devices on the Swiss market must register. This includes:

• Swiss-domiciled manufacturers selling domestically
• Foreign manufacturers (EU and non-EU) exporting to Switzerland
• Own-brand labelers (OBLs) and virtual manufacturers

Foreign manufacturers must appoint a Swiss Authorized Representative (CH REP) before registering.

Swiss Authorized Representatives (CH REP)

The CH REP serves a function analogous to the EU Authorized Representative (EC REP) under MDR Article 11. The CH REP:

• Must be established in Switzerland
• Acts as the contact point for Swissmedic and Swiss competent authorities
• Must register in swissdamed's Actor Module
• Is responsible for verifying that the manufacturer's registration data is accurate and complete
• Must maintain a copy of the technical documentation and Declaration of Conformity available for Swissmedic inspection

Importers

Importers placing devices on the Swiss market from outside Switzerland must register as economic operators in swissdamed. Importers are responsible for verifying that devices they import are registered in the Product Module and that their labeling is compliant.

System and Procedure Pack Producers

Producers of systems and procedure packs under MedDO must register as actors and register their products in the Product Module, including UDI data for the system/procedure pack as a whole.

Registration Process Step by Step

Step 1: Appoint a CH REP (Foreign Manufacturers Only)

If you are a manufacturer based outside Switzerland, you must appoint a CH REP before proceeding. The CH REP agreement must specify the scope of products covered, responsibilities, and duration. The CH REP must be registered in swissdamed's Actor Module.

Step 2: Actor Registration

Register your organization in the Actor Module as a manufacturer, CH REP, importer, or system/procedure pack producer. You will receive a CHRN (Swiss Registration Number), similar to the SRN in EUDAMED but issued by Swissmedic.

Required information for actor registration:

• Legal name and address of the organization
• Contact person details
• Role in the supply chain (manufacturer, CH REP, importer, SPPP)
• For foreign manufacturers: CH REP details
• Proof of establishment (trade registration or equivalent)

Step 3: Prepare UDI Data for Each Device

For each device you intend to register, prepare:

• Basic UDI-DI: The primary key grouping devices with the same intended purpose and risk class
• UDI-DI: The device identifier (typically GTIN) that appears on the device label
• Production identifiers: Lot/batch number, serial number, expiration date, or manufacturing date
• Device description: Name, intended purpose, risk classification
• EMDN code: European Medical Device Nomenclature classification
• Sterilization information: Whether the device is supplied sterile, method of sterilization
• Labeling information: Languages, warnings, contraindications
• Certificate linkage: Notified Body certificate numbers for devices requiring conformity assessment
• CMR substance declarations: Whether the device contains substances classified as carcinogenic, mutagenic, or toxic to reproduction
• Storage and handling conditions
• Catalogue number

Step 4: Upload Device Data to the Product Module

Data can be submitted through:

• Manual entry: Through the swissdamed web interface
• M2M (machine-to-machine): Batch uploads via API integration, available since March 2026. This is strongly recommended for manufacturers with large portfolios.

Ensure all data matches your technical documentation, labeling, and certificate records exactly. Mismatches between swissdamed data and your NB certificates will trigger queries from Swissmedic.

Step 5: Verify and Maintain

After registration:

• Verify that your data appears correctly in the swissdamed public-facing interface
• Establish a process for updating data when device specifications, labeling, or certificates change
• Monitor for any queries or validation errors from Swissmedic
• Ensure that discontinued devices are properly marked as no longer on the market

Key Differences Between swissdamed and EUDAMED

While the two systems are structurally similar, important differences exist:

Manufacturers selling in both the EU and Switzerland must maintain separate registrations in both databases. Data must be consistent between the two systems, but each requires its own submission process.

Registration Fees

Swissmedic has indicated that device registration fees will apply from January 1, 2027, though exact fee amounts have not yet been published as of May 2026. Manufacturers should budget for per-device registration fees and potentially annual maintenance fees, similar to the fee structures used by some other national databases.

Swissmedic 2026 Focus Campaign: Post-Market Surveillance

In parallel with the swissdamed rollout, Swissmedic has announced a 2026 focus campaign on post-market surveillance for higher-risk medical devices. This campaign will include targeted inspections of manufacturers' PMS systems, vigilance reporting, and PSUR compliance. The swissdamed registration status of inspected devices will be verified as part of this campaign.

This means that non-compliance with swissdamed registration may be discovered not only through database checks but also through Swissmedic's proactive inspection activities.

Consequences of Non-Compliance

The consequences of failing to register devices in swissdamed by the applicable deadline are significant:

1. Market exclusion: Devices not registered in swissdamed cannot be legally placed on the Swiss market after July 1, 2026. Distributors, hospitals, and pharmacies will be able to verify registration status.
2. Regulatory enforcement: Swissmedic may initiate enforcement actions, including product withdrawal from the Swiss market.
3. Vigilance complications: If a safety event occurs on an unregistered device, the manufacturer faces both the vigilance reporting obligation and the immediate swissdamed registration requirement simultaneously, creating regulatory and reputational risk.
4. Certificate implications: Non-compliance with registration requirements may be flagged during conformity assessment audits by Notified Bodies operating in Switzerland.
5. Supply chain disruption: Swiss importers and distributors may refuse to handle unregistered devices to protect their own compliance position.

Practical Checklist: What to Do Before July 1, 2026

For Foreign Manufacturers

• Appoint a CH REP established in Switzerland
• Register as a manufacturer in swissdamed's Actor Module
• Assign Basic UDI-DIs for all devices on the Swiss market
• Prepare UDI data for each device (description, classification, intended purpose, certificate linkage)
• Submit device data via manual entry or M2M batch upload
• Verify data accuracy against technical documentation and NB certificates
• Establish a change control process for ongoing swissdamed data maintenance
• Identify any devices likely to trigger vigilance events and prioritize their registration

For Swiss-Based Manufacturers

• Register as a manufacturer in swissdamed's Actor Module
• Prepare and submit UDI data for all devices
• Verify consistency between swissdamed data and technical documentation
• Prepare for Swissmedic's 2026 PMS focus campaign

For CH REPs

• Register as an authorized representative in swissdamed's Actor Module
• Verify manufacturer client data completeness and accuracy
• Establish processes for supporting manufacturer registration activities
• Prepare for increased client demand as the deadline approaches

Frequently Asked Questions

What is swissdamed? Swissdamed is Switzerland's national medical device database, developed by Swissmedic. It serves as the central platform for registering medical devices, IVDs, and procedure packs sold in Switzerland, including UDI data, economic operator information, and certificate records. It is Switzerland's counterpart to the EU's EUDAMED system.

When does swissdamed become mandatory? July 1, 2026. From this date, all new medical devices, IVDs, and procedure packs must be registered in swissdamed before being placed on the Swiss market.

Do I need a separate registration for Switzerland if I am already registered in EUDAMED? Yes. Switzerland is not an EU member state, and swissdamed is a separate database. You must register your devices independently in both EUDAMED (for EU market access) and swissdamed (for Swiss market access). Data should be consistent between the two systems.

What is a CH REP? A Swiss Authorized Representative (CH REP) is a person or entity established in Switzerland that acts on behalf of a foreign manufacturer for regulatory compliance purposes. The CH REP is similar to the EU Authorized Representative (EC REP) but must be based in Switzerland specifically.

What happens if a vigilance event occurs on an unregistered device? If a post-market surveillance event (incident, FSCA, or trend report) occurs on or after July 1, 2026, involving a device not yet registered in swissdamed, the device must be registered immediately. This overrides the grace period that would otherwise apply until January 1, 2027.

What is the transition period for devices already on the Swiss market? Devices already on the Swiss market before July 1, 2026, have until December 31, 2026, to be registered in swissdamed. After this date, all devices must be registered regardless of when they were first placed on the market.

Can I use M2M batch uploads for swissdamed registration? Yes. Swissmedic activated machine-to-machine (M2M) registration functionality by the end of March 2026. This allows manufacturers to submit device data in batch through API integration, which is recommended for large device portfolios.